Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy

NCT02216617 | Completed Phase 1 DMC

• 2 other identifiers: GORTEC 2013-012013-002876-42
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to determine the maximum tolerated dose (MTD) of afatinib administrated in combination with docetaxel (Taxotere®) and cisplatin in induction chemotherapy of locally advanced head and neck carcinoma in order to move to a phase II, allowing the comparison with standard induction chemotherapy TPF. It is a multicentric, national, opened, not-randomized phase Ib. Three doses of afatinib (20, 30 and 40 Mg per day) will be studied in combination with the fixed standard doses of docetaxel and cisplatin. For each dose level, beginning with smallest (20 Mg per day of afatinib), 3 to 6 patients will be treated at maximum, i.e. 3 cycles of three weeks treatment each one (9 weeks on the whole). The next dose level will be studied only if the previous dose is well tolerated for the period of the first 4 weeks observation of the treatment (1st cycle more first week of the 2nd cycle). Once the MTD is determined, four additional patients will be treated with this dose. A maximum of 22 patients should be included in this study. The total duration of the study is estimated at 18 months. In case of major safety problems, the study may be stopped earlier. In short, the preclinical data, pharmacological and clinical on afatinib indicate that the benefit-risk ratio can be regarded as positive and that the association of afatinib with cisplatin and docetaxel could be effective in patients with head and neck squamous cell carcinoma potentially resulting in an extension of time to progression.

Conditions

HNSCC

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated Dose (MTD)

  The main objective is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with docetaxel and cisplatin chemotherapy TPA induction in locally advanced head and neck carcinomas in order to move a phase II for comparison with induction chemotherapy "of reference "TPF (Taxotere, cisplatin and 5-fluorouracil).

  During the first 4 weeks of treatment for each patient of the bearing.

Secondary Outcomes (2)

• Tolerance

  12 weeks

• Efficacy

  12 weeks

Other Outcomes (1)

• Correlation between nutritional status and toxicity

  12 weeks

Study Arms (1)

Induction chemotherapy TPA

EXPERIMENTAL

3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib) 1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks) Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)

Drug: Taxotere, Cisplatin, Afatinib

Interventions

Taxotere, Cisplatin, Afatinib DRUG

Induction chemotherapy TPA

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years and ≤70 years
• Patient in first line treatment of Locally Advanced HNSCC, histologically proven non-metastatic
• At least one measurable lesion (RECIST)
• Eligible patient for standard induction chemotherapy in the opinion of the investigator; PS ECOG \< 2
• Adequacy functioning of organs, including:
• Left ventricular function with ejection fraction at rest \> 50% or as normal institutional values Haematological function
• Absolute neutrophil count (ANC) \>1,500/mm3 Special cases: ANC\> 1,000/mm3 in the opinion of the investigator and discussion with the sponsor; Platelets ≥ 75,000/mm3; Hemoglobin\> 10g/dl
• Liver function:
• Total bilirubin ≤ 1.5 x ULN; patients with Gilbert's syndrome must have a total bilirubin \<4 x ULN; SGOT and SGPT ≤ 3 x ULN or SGOT and SGPT ≤ 5 x ULN in case liver abnormalities; Alkaline phosphatase \<2.5 x ULN
• Kidney function:
• Serum creatinine \<110 umol/L or creatinine clearance \> 45 ml/min (Cockcroft method)
• General:
• Men and women of childbearing potential must agree to use a reliable contraception throughout treatment and at least 6 months after the end of treatment. Women in peri-menopause should be least 24 months of amenorrhea.
• Ability to take oral medication in the opinion of the investigator; Patient affiliated to a social security system; signed informed consent form.

You may not qualify if:

• Previous treatment with chemotherapy, radiation therapy or targeted therapy for head and neck cancer; uncontrolled Respiratory, cardiac, hepatic or renal diseases.
• Significant cardiovascular disease like:
• Cardiovascular Abnormalities considered clinically important as congestive heart failure NYHA stage ≥ III, unstable angina or myocardial infarction within the past 6 months, or arrhythmia low controlled, uncontrolled hypertension by treatment (systolic BP ≥ 160 mmHg and/or diastolic BP≥ 90 mmHg).
• Lengthening of the corrected QT interval with QTc\> 480 msec according to the formula Bazet; Bradycardia; Electrolyte disturbances
• Respiratory disease of type:
• interstitial lung disease; Pulmonary fibrosis
• Viral disease of type:
• Active infection or hepatic B virus or hepatitis C known carrier of HIV.
• Recent digestive disorder with diarrhea such as:
• Any history or presence of gastrointestinal disorders with uncontrolled diarrhea as a major symptom that may affect the absorption of drug tested in the opinion of the investigator (eg disease Crohn's disease, diarrhea CTCAE grade ≥ 2)
• Any past or present condition that would compromise the patient's ability to comply with the study or which would interfere with the evaluation of the effectiveness and the safety of the study.
• Other severe disease or condition associated with non-oncological origin likely to be incompatible with the protocol in the judgment of the investigator.
• Patient already included in another clinical trial with an experimental molecule; Persons deprived of liberty or under guardianship or as backup justice.
• Patient requiring prohibited concomitant treatments with study.
• Any cons-indication to treatment with Taxotere or Afatinib or cisplatin.

Sponsors & Collaborators

• Groupe Oncologie Radiotherapie Tete et Cou: lead

Study Sites (1)

ICM Val d'Aurelle, Montpellier

Montpellier, 34298, France

Location

Related Links

• Related Info

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

Docetaxel; Cisplatin; Afatinib

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Amides; Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Didier CUPISSOL, MD

  GORTEC

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2014
• First Posted: August 15, 2014
• Study Start: August 6, 2014
• Primary Completion: July 1, 2015
• Study Completion: September 15, 2015
• Last Updated: October 27, 2017

Record last verified: 2017-10

Locations

FR (1)